Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

What happened

Beta Bionics reported third quarter 2026 net sales of $35.5 million, up 30% from $27.3 million a year earlier. Gross margin was 57.3%, while net loss was $24.4 million and the company updated its full year 2026 guidance.

Confirmed

Global impact / market context

Sales are growing strongly, led by the pharmacy benefit channel, which means insurance coverage through pharmacies rather than equipment suppliers. But losses widened to $24.4 million, so the company still spends more than it earns and may need outside funding or cost cuts.

Analyst inference

The pharmacy channel grew 118% while the equipment channel grew only 4%, showing a shift in how patients get reimbursed. Faster growth there can lift revenue, but widening losses and rising spending mean investors will weigh expansion against the path to profitability.

Analyst inference

What to watch

1. Watch fourth quarter net sales and gross margin against the updated full year 2026 guidance, since those figures will show whether the 30% sales growth and 57.3% margin held through year end. Confirmed
2. Watch whether the company slows spending or raises new money, because a $24.4 million quarterly net loss and negative adjusted EBITDA mean cash available could shrink without funding or cost cuts. Proposed
3. Watch the mix of new patient starts: 69% came from multiple daily injections and a high-30s percentage from the pharmacy channel, so further pharmacy growth could lift revenue but change costs and profit per sale. Analyst inference

Evidence

• globenewswire.com